Tumor pretargeting

Role of avidin/streptavidin on monoclonal antibody internalization

Patrizia Casalini, Elena Luison, Sylvie Ménard, Maria I. Colnaghi, Giovanni Paganelli, Silvana Canevari

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Radioimmunodetection of tumor can be improved by introducing a two-step system in which radiolabeled streptavidin is administrated after the injection of a biotinylated monoclonal antibody (MAb) (two-step) or radiolabeled biotin is injected after biotinylated MAb and avidin (three- step). The anti-carcinoembryonic antigen (CEA) MAb FO23C5 has been recently exploited in a three-step protocol based on the avidin-biotin system. The anti-folate receptor (FR) MAb MOv18 has proven suitable for radioimmunodetection of ovarian cancer using directly radiolabeled MAb or in a two-step method. In this study, we analyzed the suitability of MOv18 in a three-step protocol in ovarian carcinoma patients and the internalization events after formation of the MOv18-avidin complex. Methods: Selected patients with documented metastatic lesions were enrolled in a three-step radioimaging analysis with biotinylated MOv18 and FO23C5, avidin and 111In-labeled biotin. Two-step internalization experiments were conducted in vitro with MOv18 and MOv19 MAbs on the FR-overexpressing IGROV1 cell line and with the anti-CEA MAb FO23C5 on the LS174T cell line. Cells were incubated sequentially with biotinylated MAb and 125I-labeled streptavidin or with 125I-biotinylated MAb and cold streptavidin. Results: In the in vivo study, SPECT revealed the majority of metastatic lesions in patients injected with biotinylated MOv18; however, the tumor-to-background ratio was relatively low. In the in vitro study, a consistent internalization was induced by antigen-biotinylated MAb-streptavidin complex formation at the cell surface in both antigenic systems analyzed. However, the extent of internalization was lower in the CEA model. Conclusion: The internalization ability of avidin suggests its potential clinical application for delivering toxic agents in a two-step approach (biotinylated MAb + avidin conjugate). The suitability of a given MAb for three-step clinical applications (biotinylated MAb + avidin + biotin) should be previously investigated by using appropriate in vitro experiments.

Original languageEnglish
Pages (from-to)1378-1381
Number of pages4
JournalJournal of Nuclear Medicine
Volume38
Issue number9
Publication statusPublished - Sep 1997

Fingerprint

Streptavidin
Avidin
Monoclonal Antibodies
Biotin
Neoplasms
Carcinoembryonic Antigen
Radioimmunodetection
Folic Acid
Cell Line
Poisons
Single-Photon Emission-Computed Tomography
Ovarian Neoplasms
Carcinoma
Antigens
Injections

Keywords

  • Avidin
  • Cellular internalization
  • Monoclonal antibody
  • Streptavidin
  • Tumor pretargeting

ASJC Scopus subject areas

  • Radiological and Ultrasound Technology

Cite this

Casalini, P., Luison, E., Ménard, S., Colnaghi, M. I., Paganelli, G., & Canevari, S. (1997). Tumor pretargeting: Role of avidin/streptavidin on monoclonal antibody internalization. Journal of Nuclear Medicine, 38(9), 1378-1381.

Tumor pretargeting : Role of avidin/streptavidin on monoclonal antibody internalization. / Casalini, Patrizia; Luison, Elena; Ménard, Sylvie; Colnaghi, Maria I.; Paganelli, Giovanni; Canevari, Silvana.

In: Journal of Nuclear Medicine, Vol. 38, No. 9, 09.1997, p. 1378-1381.

Research output: Contribution to journalArticle

Casalini, P, Luison, E, Ménard, S, Colnaghi, MI, Paganelli, G & Canevari, S 1997, 'Tumor pretargeting: Role of avidin/streptavidin on monoclonal antibody internalization', Journal of Nuclear Medicine, vol. 38, no. 9, pp. 1378-1381.
Casalini P, Luison E, Ménard S, Colnaghi MI, Paganelli G, Canevari S. Tumor pretargeting: Role of avidin/streptavidin on monoclonal antibody internalization. Journal of Nuclear Medicine. 1997 Sep;38(9):1378-1381.
Casalini, Patrizia ; Luison, Elena ; Ménard, Sylvie ; Colnaghi, Maria I. ; Paganelli, Giovanni ; Canevari, Silvana. / Tumor pretargeting : Role of avidin/streptavidin on monoclonal antibody internalization. In: Journal of Nuclear Medicine. 1997 ; Vol. 38, No. 9. pp. 1378-1381.
@article{28830d51bed44e3e9d3297bc44fcba40,
title = "Tumor pretargeting: Role of avidin/streptavidin on monoclonal antibody internalization",
abstract = "Radioimmunodetection of tumor can be improved by introducing a two-step system in which radiolabeled streptavidin is administrated after the injection of a biotinylated monoclonal antibody (MAb) (two-step) or radiolabeled biotin is injected after biotinylated MAb and avidin (three- step). The anti-carcinoembryonic antigen (CEA) MAb FO23C5 has been recently exploited in a three-step protocol based on the avidin-biotin system. The anti-folate receptor (FR) MAb MOv18 has proven suitable for radioimmunodetection of ovarian cancer using directly radiolabeled MAb or in a two-step method. In this study, we analyzed the suitability of MOv18 in a three-step protocol in ovarian carcinoma patients and the internalization events after formation of the MOv18-avidin complex. Methods: Selected patients with documented metastatic lesions were enrolled in a three-step radioimaging analysis with biotinylated MOv18 and FO23C5, avidin and 111In-labeled biotin. Two-step internalization experiments were conducted in vitro with MOv18 and MOv19 MAbs on the FR-overexpressing IGROV1 cell line and with the anti-CEA MAb FO23C5 on the LS174T cell line. Cells were incubated sequentially with biotinylated MAb and 125I-labeled streptavidin or with 125I-biotinylated MAb and cold streptavidin. Results: In the in vivo study, SPECT revealed the majority of metastatic lesions in patients injected with biotinylated MOv18; however, the tumor-to-background ratio was relatively low. In the in vitro study, a consistent internalization was induced by antigen-biotinylated MAb-streptavidin complex formation at the cell surface in both antigenic systems analyzed. However, the extent of internalization was lower in the CEA model. Conclusion: The internalization ability of avidin suggests its potential clinical application for delivering toxic agents in a two-step approach (biotinylated MAb + avidin conjugate). The suitability of a given MAb for three-step clinical applications (biotinylated MAb + avidin + biotin) should be previously investigated by using appropriate in vitro experiments.",
keywords = "Avidin, Cellular internalization, Monoclonal antibody, Streptavidin, Tumor pretargeting",
author = "Patrizia Casalini and Elena Luison and Sylvie M{\'e}nard and Colnaghi, {Maria I.} and Giovanni Paganelli and Silvana Canevari",
year = "1997",
month = "9",
language = "English",
volume = "38",
pages = "1378--1381",
journal = "Journal of Nuclear Medicine",
issn = "0161-5505",
publisher = "Society of Nuclear Medicine Inc.",
number = "9",

}

TY - JOUR

T1 - Tumor pretargeting

T2 - Role of avidin/streptavidin on monoclonal antibody internalization

AU - Casalini, Patrizia

AU - Luison, Elena

AU - Ménard, Sylvie

AU - Colnaghi, Maria I.

AU - Paganelli, Giovanni

AU - Canevari, Silvana

PY - 1997/9

Y1 - 1997/9

N2 - Radioimmunodetection of tumor can be improved by introducing a two-step system in which radiolabeled streptavidin is administrated after the injection of a biotinylated monoclonal antibody (MAb) (two-step) or radiolabeled biotin is injected after biotinylated MAb and avidin (three- step). The anti-carcinoembryonic antigen (CEA) MAb FO23C5 has been recently exploited in a three-step protocol based on the avidin-biotin system. The anti-folate receptor (FR) MAb MOv18 has proven suitable for radioimmunodetection of ovarian cancer using directly radiolabeled MAb or in a two-step method. In this study, we analyzed the suitability of MOv18 in a three-step protocol in ovarian carcinoma patients and the internalization events after formation of the MOv18-avidin complex. Methods: Selected patients with documented metastatic lesions were enrolled in a three-step radioimaging analysis with biotinylated MOv18 and FO23C5, avidin and 111In-labeled biotin. Two-step internalization experiments were conducted in vitro with MOv18 and MOv19 MAbs on the FR-overexpressing IGROV1 cell line and with the anti-CEA MAb FO23C5 on the LS174T cell line. Cells were incubated sequentially with biotinylated MAb and 125I-labeled streptavidin or with 125I-biotinylated MAb and cold streptavidin. Results: In the in vivo study, SPECT revealed the majority of metastatic lesions in patients injected with biotinylated MOv18; however, the tumor-to-background ratio was relatively low. In the in vitro study, a consistent internalization was induced by antigen-biotinylated MAb-streptavidin complex formation at the cell surface in both antigenic systems analyzed. However, the extent of internalization was lower in the CEA model. Conclusion: The internalization ability of avidin suggests its potential clinical application for delivering toxic agents in a two-step approach (biotinylated MAb + avidin conjugate). The suitability of a given MAb for three-step clinical applications (biotinylated MAb + avidin + biotin) should be previously investigated by using appropriate in vitro experiments.

AB - Radioimmunodetection of tumor can be improved by introducing a two-step system in which radiolabeled streptavidin is administrated after the injection of a biotinylated monoclonal antibody (MAb) (two-step) or radiolabeled biotin is injected after biotinylated MAb and avidin (three- step). The anti-carcinoembryonic antigen (CEA) MAb FO23C5 has been recently exploited in a three-step protocol based on the avidin-biotin system. The anti-folate receptor (FR) MAb MOv18 has proven suitable for radioimmunodetection of ovarian cancer using directly radiolabeled MAb or in a two-step method. In this study, we analyzed the suitability of MOv18 in a three-step protocol in ovarian carcinoma patients and the internalization events after formation of the MOv18-avidin complex. Methods: Selected patients with documented metastatic lesions were enrolled in a three-step radioimaging analysis with biotinylated MOv18 and FO23C5, avidin and 111In-labeled biotin. Two-step internalization experiments were conducted in vitro with MOv18 and MOv19 MAbs on the FR-overexpressing IGROV1 cell line and with the anti-CEA MAb FO23C5 on the LS174T cell line. Cells were incubated sequentially with biotinylated MAb and 125I-labeled streptavidin or with 125I-biotinylated MAb and cold streptavidin. Results: In the in vivo study, SPECT revealed the majority of metastatic lesions in patients injected with biotinylated MOv18; however, the tumor-to-background ratio was relatively low. In the in vitro study, a consistent internalization was induced by antigen-biotinylated MAb-streptavidin complex formation at the cell surface in both antigenic systems analyzed. However, the extent of internalization was lower in the CEA model. Conclusion: The internalization ability of avidin suggests its potential clinical application for delivering toxic agents in a two-step approach (biotinylated MAb + avidin conjugate). The suitability of a given MAb for three-step clinical applications (biotinylated MAb + avidin + biotin) should be previously investigated by using appropriate in vitro experiments.

KW - Avidin

KW - Cellular internalization

KW - Monoclonal antibody

KW - Streptavidin

KW - Tumor pretargeting

UR - http://www.scopus.com/inward/record.url?scp=0030883111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030883111&partnerID=8YFLogxK

M3 - Article

VL - 38

SP - 1378

EP - 1381

JO - Journal of Nuclear Medicine

JF - Journal of Nuclear Medicine

SN - 0161-5505

IS - 9

ER -